Trial results

A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients

NCT06254014 on ClinicalTrials.gov · last registry update 2025-09-18

Closed to new participants; the 270 already enrolled are still being followed. Its estimated completion date, 1 May 2026, has passed with no update to the record. Primary outcome, as filed: HbA1c. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status

ACTIVE_NOT_RECRUITING

Phase

P3

Drug

exenatide

Byetta, Bydureon

Sponsor

Beijing Dongfang Biotech Co., Ltd.

Sponsor type

Industry

Enrollment

270

Started

2024-07-10

Primary completion

2026-05-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

HbA1c

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.